The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
Endocrine therapy plus CDK 4/6i represents an effective treatment, regardless of HER2 status (low/zero). Second-line agents did not differ significantly in terms of TTD. Endocrine resistant cancers exhibit poor response to CDK 4/6i.
Authors
- Elena Collovà
- Ferdinando Riccardi (ORCID: https://orcid.org/0000-0002-2852-2770)
- Fabio Puglisi (ORCID: https://orcid.org/0000-0003-0573-4938)
- Claudia Bighin
- Eva Blondeaux (ORCID: https://orcid.org/0000-0001-9566-4579)
- Michelino De Laurentiis (ORCID: https://orcid.org/0000-0001-9009-1572)
- Grazia Arpino (ORCID: https://orcid.org/0000-0002-4074-2530)
- Marco Bruzzone (ORCID: https://orcid.org/0000-0002-8821-4542)
- Tommaso Ruelle
- Valentina Sini
- Chiara Molinelli
- Lucia Del Mastro (ORCID: https://orcid.org/0000-0002-9546-5841)
- Stefania Russo (ORCID: https://orcid.org/0000-0003-0114-8042)
- Matteo Lambertini (ORCID: https://orcid.org/0000-0003-1797-5296)
- Chiara Lanzavecchia
- Alessandra Fabi (ORCID: https://orcid.org/0000-0002-6320-2609)
- Andrea Fontana (ORCID: https://orcid.org/0000-0003-2496-2506)
- Francesco Cognetti
- Palma Pugliese
Institutions
- Agostino Gemelli University Polyclinic (IT)
- Ospedale Antonio Cardarelli (IT)
- National Cancer Institute (UA)
- National Cancer Institute (MY)
- Ospedale Regina Margherita (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Ospedale Policlinico San Martino (IT)
- Ospedale Sant'Anna (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Aziende Socio Sanitarie Territoriale Ovest Milanese
- University of Naples Federico II (IT)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1016/j.ejca.2024.115113
- Citations
- 12
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 5.03
Funders
- Fondazione Umberto Veronesi